Our Lymphocyte Subset Profile & Absolute Cell Count Analysis (TBNK FACS) delivers a high-resolution quantitative snapshot of T, B, and NK cell populations, alongside their absolute counts, from a single peripheral blood sample. Our service combines multicolor flow cytometric immunophenotyping with rigorous quality-controlled gating strategies and standardized reference ranges, ensuring precise enumeration of CD3⁺, CD4⁺, CD8⁺, CD19⁺, and CD16⁺/CD56⁺ subsets. By providing both relative percentages and absolute cell numbers with rapid turnaround, we empower you to accurately assess immune competence, monitor disease progression or therapy response, and stratify patients for personalized immunomodulatory interventions.
The TBNK fluorescence-activated cell sorting (FACS) assay is a high-dimensional flow cytometric platform that simultaneously delineates the major lymphocyte lineages, T, B, and natural killer cells, along with their critical CD4⁺ and CD8⁺ T cell subsets, through multi‑parametric immunophenotyping. This methodology confers decisive advantages over conventional techniques, including ultra‑high multiplexing capacity, single‑cell resolution, rapid acquisition of statistically robust counts from minute sample volumes, and, with the adoption of volumetric absolute counting or bead‑based reference standardization, exceptional inter‑laboratory reproducibility and traceability to international units. Such attributes render TBNK FACS the indispensable gold‑standard tool for generating a comprehensive lymphocyte subset profile, enabling precise evaluation of immune competence, dynamic tracking of disease progression
Fig.1 T cell signatures relevant to the performance of CAR-T cell treatment. 1
Our Lymphocyte Subset Profile & Absolute Cell Count Analysis (TBNK FACS) delivers high‑precision enumeration of T, B, and NK cells with absolute quantification. Our service enables immune status monitoring, disease progression tracking, and therapeutic response evaluation. Leveraging standardized multicolor flow cytometry and rigorous quality controls, we provide reliable, clinically actionable data tailored to research and diagnostic needs.
Our portfolio delivers three complementary TBNK profiling solutions, bead-based absolute counting for regulatory-grade precision, volumetric flow cytometry for high-throughput efficiency, and dual-platform integration for cost-effective flexibility, ensuring tailored immunomonitoring.
Required Starting Materials: Anticoagulated peripheral whole blood, or thawed or fresh PBMCs.
Q1: What is the primary clinical purpose of this test?
A1: This assay provides a quantitative assessment of a patient's cellular immune status by enumerating T cells, B cells, and NK cells, which is critical for diagnosing immunodeficiencies, monitoring HIV infection and immune reconstitution post-transplant.
Q2: Which diseases or conditions is this test used to monitor?
A2: It is essential for managing a broad spectrum of conditions, including HIV infection, primary and secondary immunodeficiencies, and monitoring therapeutic efficacy in autoimmune diseases, cancers, and chronic infections like brucellosis.
Q3: How are the results interpreted in specific diseases?
A3: In HIV, a low CD4⁺ T-cell count indicates disease progression and guides prophylaxis; in cancers, a decreased CD4⁺/CD8⁺ ratio often suggests immune suppression and poorer prognosis, while in type 2 diabetes, an elevated ratio may be observed
Our advanced TBNK FACS panel delivers precise lymphocyte subset quantification with absolute counts, ensuring high-resolution immune profiling. We combine rigorous quality control, standardized protocols, and rapid turnaround to support clinical diagnostics and research. Count on our expertise for reproducible, actionable data.
"Their service not only provided standard percentages for CD3⁺/CD4⁺/CD8⁺ T cells, CD19⁺ B cells, and CD16⁺ CD56⁺ NK cells, but more importantly, delivered highly reproducible absolute cell concentration data using absolute count beads." Dr. K* T*.
"Our team is developing a bispecific antibody targeting autoimmune diseases. Their service helped us track the real-time dynamics of B cells, NK cells, and various T lymphocyte subsets in whole blood samples post-dosing. What impressed us most was their analytical report, it provided comprehensive data on the core TBNK subsets while seamlessly integrating auxiliary markers tailored to our specific study needs." Dr. X*m* C*.
For advanced immune profiling support, connect directly with our scientific liaison team by phone or email, whether for tailored panel development, technical consultation, or expedited quotation. We invite you to outline your project requirements and discover our precision-oriented services. Reach out now to initiate a collaborative discussion.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION